UCB, a global biopharmaceutical company, is presenting its research on generalized myasthenia gravis (gMG) at two annual meetings. It will present additional results from the MycarinG and RAISE studies on its drugs rozanolixizumab-noli and zilucoplan. Both drugs, recently approved by the US FDA and Japanese authorities, are under review by the European Medicines Agency for the treatment of adults with gMG. UCB is also assessing the drugs in pediatric patients with gMG.
News alert: Hybrid Analysis adds Criminal IP’s real-time domain scans, boosts malware detection – Security Boulevard
Security Boulevard reports that Hybrid Analysis has enhanced its malware detection capabilities by integrating real-time domain scans of Criminal IP’s. This addition is expected to
